FORT COLLINS, Colo. – April 4, 2012 – Ventria Bioscience has announced the successful completion of a phase 2 clinical trial of its lead therapeutic candidate, VEN100. The study was conducted by a team of investigators from the Department of Epidemiology, Division of Infectious Diseases, and Division of Geriatric Medicine at Johns Hopkins University (Baltimore, Md.). The randomized, double-blind, placebo-controlled study tested the safety and tolerability of VEN100 and its ability to reduce the incidence of antibiotic-associated diarrhea (AAD) in high-risk patients. The results showed a 52 percent relative risk reduction (RRR) and a 47.9 percent absolute risk reduction (ARR) in the incidence of diarrhea in the placebo versus VEN100 treatment groups (92.3 vs. 44.4 percent, respectively; P = 0.023). Thus, patients treated with VEN100 concurrently with antibiotic treatment were at a significantly reduced risk of experiencing diarrhea compared to the participants in the control group (the odds ratio was 0.07 [95% CI, 0.001–0.97]). VEN100 was also found to be safe and well tolerated, with no observed adverse events in the study.